within Pharmacolibrary.Drugs.R_RespiratorySystem.R03D_OtherSystemicDrugsForObstructiveAirwayDiseases.R03DA04_Theophylline;

model Theophylline_1
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 3.2666666666666666e-06,
    adminDuration = 600,
    adminMass = 250 / 1000000,
    adminCount = 1,
    Vd = 0.025,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.012,
    k12 = 1.0277777777777777e-05,
    k21 = 1.0277777777777777e-05);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Theophylline_1</td></tr><tr><td>ATC code:</td><td>R03DA04_1</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>250</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>25</td><td>L</td></tr>
    <tr><td>clearance:</td><td>2.8</td><td>mL/min/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Theophylline is a methylxanthine drug used as a bronchodilator, primarily for asthma and COPD. Although it has been largely superseded by newer drugs, it continues to have clinical utility in specific cases.</p><h4>Pharmacokinetics</h4><p>Two-compartment pharmacokinetic model in healthy adults, after intravenous administration.</p><h4>References</h4><ol><li><p>Yano, I, et al., &amp; Hori, R (1993). Population pharmacokinetics of theophylline. I: Intravenous infusion to children in the acute episode of asthma. <i>Biological &amp; pharmaceutical bulletin</i> 16(1) 59–62. DOI:<a href=\"https://doi.org/10.1248/bpb.16.59\">10.1248/bpb.16.59</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/8369754/\">https://pubmed.ncbi.nlm.nih.gov/8369754</a></p></li><li><p>Yano, I, et al., &amp; Hori, R (1993). Population pharmacokinetics of theophylline. II: Intravenous infusion to patients with stable chronic airway obstruction. <i>Biological &amp; pharmaceutical bulletin</i> 16(5) 501–505. DOI:<a href=\"https://doi.org/10.1248/bpb.16.501\">10.1248/bpb.16.501</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/8364499/\">https://pubmed.ncbi.nlm.nih.gov/8364499</a></p></li><li><p>Moore, ES, et al., &amp; Grasela, TH (1989). The population pharmacokinetics of theophylline in neonates and young infants. <i>Journal of pharmacokinetics and biopharmaceutics</i> 17(1) 47–66. DOI:<a href=\"https://doi.org/10.1007/BF01059087\">10.1007/BF01059087</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/2715932/\">https://pubmed.ncbi.nlm.nih.gov/2715932</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.R.R03DA04_1 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Theophylline_1;
